Evoke Pharma (EVOK) Competitors

Mural Oncology (NASDAQ:MURA) and Evoke Pharma (NASDAQ:EVOK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Which has more volatility and risk, MURA or EVOK?

Mural Oncology has a beta of 3, meaning that its stock price is 200% more volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500.

Which has preferable earnings and valuation, MURA or EVOK?

Evoke Pharma has higher revenue and earnings than Mural Oncology. Evoke Pharma is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mural Oncology	N/A	N/A	-$128.51M	-$8.59	-0.20
Evoke Pharma	$11.59M	0.66	-$5.35M	-$2.56	-2.00

Does the media prefer MURA or EVOK?

In the previous week, Evoke Pharma had 7 more articles in the media than Mural Oncology. MarketBeat recorded 10 mentions for Evoke Pharma and 3 mentions for Mural Oncology. Mural Oncology's average media sentiment score of 0.85 beat Evoke Pharma's score of 0.19 indicating that Mural Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mural Oncology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evoke Pharma	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate MURA or EVOK?

Mural Oncology currently has a consensus price target of $12.00, suggesting a potential upside of 581.82%. Given Mural Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe Mural Oncology is more favorable than Evoke Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mural Oncology	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Evoke Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is MURA or EVOK more profitable?

Mural Oncology has a net margin of 0.00% compared to Evoke Pharma's net margin of -42.07%. Evoke Pharma's return on equity of -93.51% beat Mural Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mural Oncology	N/A	-107.76%	-87.57%
Evoke Pharma	-42.07%	-93.51%	-33.60%

Do institutionals and insiders have more ownership in MURA or EVOK?

80.2% of Mural Oncology shares are held by institutional investors. 2.2% of Mural Oncology shares are held by company insiders. Comparatively, 2.3% of Evoke Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Mural Oncology beats Evoke Pharma on 8 of the 15 factors compared between the two stocks.